The Mechanics of Pharma M&A with Gilead’s Devang Bhuta: Bhuta, Gilead’s SVP of corporate development, sits down with Kinara’s Chase Feiger to address the many myths and outdated assumptions around M&A efforts in the current financial climate. He discusses the need to “stay close to the science” amid the deal-making back and forth as well as his belief that each integration, whether of an asset, a team or a company, is truly unique. Bhuta also acknowledges the “competitive tension” that flares during the process and details the approaches he has adopted to most effectively deflate it.